Experimental therapy offers hope for kids with Tough-to-Treat leukemia
NCT ID NCT07078929
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new type of CAR T-cell therapy (CMD63) in 16 children whose B-cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The therapy uses specially engineered immune cells to target and kill cancer cells. The main goal is to check safety and see how well it works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFACTORY CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
King Chulalongkorn Memorial Hospital
RECRUITINGBangkok, Pathumwan, 10330, Thailand
-
Maharaj Nakorn Chiang Mai Hospital
NOT_YET_RECRUITINGChiang Mai, Mueang Chiang Mai District, 50200, Thailand
-
Siriraj Hospital
NOT_YET_RECRUITINGBangkok, Bangkoknoi, 10700, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.